Literature DB >> 16116953

Dual effect of 3,4-dihydroxyacetophenone on LPS-induced apoptosis in RAW264.7 cells by modulating the production of TNF-alpha.

Ping Wu1, Duyun Ye, Daijuan Zhang, Li Zhang, Jingyuan Wan, Qian Pan.   

Abstract

To explore the pharmacological effect of 3,4-dihydroxyacetophenone (DHAP) on the apoptosis of RAW264.7 macrophage cells and the mechanism, RAW264.7 macrophage cells were treated with 100 or 500 mg/L lipopolysaccharide (LPS), with or without 10(-5) mol/L DHAP for 24 h. Trypan blue dye exclusion assay was used to assess cell viability. Cell apoptosis was morphological studied and flow cytometric assay was used. Tumor necrosis factor-alpha (TNF-alpha) level was measured by ELISA methods. IkappaB protein was determined by Western blotting. Our results showed that in 100 mg/L LPS-stimulated macrophages, DHAP enhanced the cell apoptosis while in 500 mg/L LPS-stimulated macrophages, DHAP significantly inhibited the cell apoptosis. In both groups, DHAP increased the level of IkappaB but decreased the level of TNF-alpha. It is concluded that DHAP has dual effect on the apoptosis of RAW 264.7 cells treated with different concentrations of LPS. This effect may be due to the inhibition of activation of NF-kappaB and autocrine production of TNFalpha. Our study suggests that DHAP may have anti-inflammatory effect on LPS-activated macrophages.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16116953     DOI: 10.1007/BF02873557

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  15 in total

Review 1.  Pathogen-induced apoptosis of macrophages: a common end for different pathogenic strategies.

Authors:  W W Navarre; A Zychlinsky
Journal:  Cell Microbiol       Date:  2000-08       Impact factor: 3.715

Review 2.  Granulocyte apoptosis and inflammatory disease.

Authors:  C Haslett
Journal:  Br Med Bull       Date:  1997       Impact factor: 4.291

3.  Possible new role for NF-kappaB in the resolution of inflammation.

Authors:  T Lawrence; D W Gilroy; P R Colville-Nash; D A Willoughby
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

Review 4.  Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal.

Authors:  Takashi Tsuruo; Mikihiko Naito; Akihiro Tomida; Naoya Fujita; Tetsuo Mashima; Hiroshi Sakamoto; Naomi Haga
Journal:  Cancer Sci       Date:  2003-01       Impact factor: 6.716

5.  Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages.

Authors:  S Hortelano; A Castrillo; A M Alvarez; L Boscá
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

6.  Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-kappaB/IkappaB- and ERK2-dependent mechanisms.

Authors:  Sonia Eligini; Marta Brambilla; Cristina Banfi; Marina Camera; Luigi Sironi; Silvia Stella Barbieri; Johan Auwerx; Elena Tremoli; Susanna Colli
Journal:  Cardiovasc Res       Date:  2002-08-01       Impact factor: 10.787

7.  Effects of 3,4-dihydroxyacetophenone on the biosynthesis of TXA2 and PGI2 in human placental villus and umbilical artery segments in vitro.

Authors:  D S Yang; W Xi-rui; M Ting-yuan
Journal:  Prostaglandins       Date:  1989-10

Review 8.  Apoptosis as a therapeutic tool in rheumatoid arthritis.

Authors:  Richard M Pope
Journal:  Nat Rev Immunol       Date:  2002-07       Impact factor: 53.106

9.  NF-kappaB and AP-1 activation by nitric oxide attenuated apoptotic cell death in RAW 264.7 macrophages.

Authors:  A von Knethen; D Callsen; B Brüne
Journal:  Mol Biol Cell       Date:  1999-02       Impact factor: 4.138

10.  [Effect of 3,4-dihydroxyacetophenone treatment on intrauterine growth retardation].

Authors:  Y P Huang; T Y Ma
Journal:  Zhonghua Fu Chan Ke Za Zhi       Date:  1993-06
View more
  1 in total

1.  3,4‑Dihydroxyacetophenone attenuates oxidative stress‑induced damage to HUVECs via regulation of the Nrf2/HO‑1 pathway.

Authors:  Daihong Cao; Yunhan Wang; Wentao Li; Jiafen Ji; Juntang Guo; Daijuan Zhang; Jiangyue Liu
Journal:  Mol Med Rep       Date:  2022-04-27       Impact factor: 3.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.